(CTNM) Contineum Therapeutics - Ratings and Ratios

Contineum Therapeutics, Inc. (NASDAQ:CTNM) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel oral small molecule therapies targeting high unmet needs in neuroscience, inflammation, and immunology. The companys lead candidate, PIPE-791, is a brain-penetrant small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R), currently in development for idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). PIPE-791s ability to cross the blood-brain barrier positions it as a promising candidate for central nervous system (CNS) disorders. Additionally, the company is advancing PIPE-307, a selective M1 receptor inhibitor, for depression and relapse-remitting MS, and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, rebranded from Pipeline Therapeutics, Inc. in November 2023, has been operational since its incorporation in 2009 and is headquartered in San Diego, California. The companys strategic focus on CNS and inflammatory diseases aligns with growing demand for innovative therapies in these areas.

Ticker Symbol: CTNM Exchange: NASDAQ Type: common stock Country Origin: United States GICS Sub Industry: Pharmaceuticals

3-month forecast: Based on and , CTNM is expected to face near-term volatility. The stock is currently trading below its 20, 50, and 200-day moving averages, indicating a downtrend. With an average volume of 52,887 shares over 20 days, liquidity remains low, which could amplify price swings. The ATR of 0.68 suggests moderate volatility. On the fundamental side, the companys negative return on equity (-16.87%) and high P/B ratio (2.27) signal elevated risk. However, the market capitalization of $493.12M reflects investor confidence in its pipeline. Investors should monitor clinical trial progress and potential catalysts, as positive developments could drive upside. The lack of forward P/E and P/S highlights the speculative nature of the stock, typical for early-stage biotech companies.